Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-03-27 Declaration of Voting R…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend declarations, and the election of board members. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-03-27 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for JW Pharmaceutical Corporation, covering the fiscal year 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes (주석). It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) or business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2023
2024-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, financial highlights (consolidated and separate), and details regarding the auditor (Ernst & Young Han Young). While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains the scheduling conflict for the upcoming AGM. Since it is a specific regulatory disclosure regarding meeting logistics and does not fit into the other categories like AGM-R (presentation materials) or PSI (proxy solicitation), it falls under the general regulatory filing category.
2024-02-27 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for JW Pharmaceutical. It contains the agenda for the 68th Annual General Meeting, including items for approval such as financial statements, board appointments, and remuneration limits. It also includes detailed management information, business overviews, and financial summaries (balance sheets and income statements) typically provided to shareholders in advance of an AGM. This aligns with the definition of Proxy Solicitation & Information Statement (PSI) as it provides information and requests votes for the meeting.
2024-02-27 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation). It contains information regarding the upcoming Annual General Meeting (AGM), including agenda items like approval of financial statements, election of directors, and remuneration limits. This document is specifically designed to solicit votes from shareholders for the meeting, fitting the definition of a Proxy Solicitation & Information Statement.
2024-02-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.